Sabby Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Sabby Management’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,171	Closed	-$234K	–	94
2023 Q3	$234K	Sell	1,171 -429	-27%	-$94.5K	0.17%	32
2023 Q2	$432K	Sell	1,600 -1,206	-43%	-$250K	0.35%	34
2023 Q1	$551K	Sell	2,806 -1,147	-29%	-$256K	0.48%	21
2022 Q4	$615K	Sell	3,953 -265	-6%	-$60.4K	0.54%	23
2022 Q3	$1.25M	Sell	4,218 -20	-0.5%	-$7.2K	1.58%	16
2022 Q2	$1.78M	Buy	4,238 +217	+5%	+$89K	1.21%	14
2022 Q1	$18.3M	Buy	4,021 +514	+15%	+$300K	2.74%	8
2021 Q4	$3.01M	Sell	3,507 -465	-12%	-$479K	0.44%	33
2021 Q3	$4.77M	Buy	3,972 +3,353	+542%	+$7.02M	0.64%	18
2021 Q2	$704K	Sell	619 -181	-23%	-$194K	0.1%	97
2021 Q1	$942K	Buy	+800	New	+$1.07M	0.18%	82

Other funds holding VRPX

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sabby Management's VRPX Position: Q4 2023 in Review

Sabby Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q4 2023, closing a stake of 1,171 shares — an estimated $234K sold.

Sabby Management first reported a position in VRPX in Q1 2021 and held it in 11 quarters. The position peaked at $18.3M in Q1 2022. 15 funds tracked by Wall St. Rank hold VRPX as of Q4 2023.

Sabby Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Sabby Management sold 1,171 Virpax Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $234K.
Sabby Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Sabby Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $18.3M in Q1 2022.
15 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.